Skip to main content

Neuer Inhalt Free registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

02-21-2018 | Primary care | Editorial | Article

Compassion fatigue in diabetes care professionals

Awareness and education about compassion fatigue can help to limit its incidence and severity. Sanjay Kalra outlines strategies to identify and manage the emotional exhaustion that often affects diabetes caregivers.

03-12-2018 | Canagliflozin | News

CANVAS analysis supports SGLT2 inhibitor benefits for HF

The latest analysis of the CANVAS trial indicates that the cardiovascular benefits of canagliflozin in patients with type 2 diabetes may be greatest in those with concomitant heart failure.

03-09-2018 | Healthcare systems | Editorial | Article

My journey into diabetes nursing: A perspective from the UK National Health Service

Diabetes nurse consultant and Advisory Board member, Maureen Wallymahmed reflects on her experiences within the profession and charts the evolution of the role over the past 40 years.

Latest from across the site

03-19-2018 | Obesity | News

Further evidence challenges obesity paradox

UK Biobank data add to the evidence challenging the existence of the obesity paradox by showing that cardiovascular disease risk increases linearly with increasing adiposity in middle-aged men and women.


Eur Heart J 2018; Advance online publication

03-16-2018 | Dipeptidyl peptidase-4 inhibitors | News

DUKPC 2018 in brief

‘Drastic’ changes in second-line prescribing patterns for type 2 diabetes in the UK

An analysis of electronic health records reveals changes in prescribing patterns for type 2 diabetes treatments in the UK over the past decade.

03-16-2018 | Sodium-glucose cotransporter-2 inhibitors | News

DUKPC 2018

eGFR within normal range predictive of SGLT2 inhibitor response

Kidney function predicts patients’ response to SGLT2 inhibitors even in patients with normal estimated glomerular filtration rate, show real-world data.

03-16-2018 | Empagliflozin | News

DUKPC 2018

Cardiovascular benefits of empagliflozin occur regardless of HbA1c levels

Analysis of data from the EMPA-REG OUTCOME trial suggests that empagliflozin reduces the risk for cardiovascular mortality in patients with type 2 diabetes irrespective of baseline glycated hemoglobin levels or glycemic response.

03-16-2018 | Complications | News

DUKPC 2018 in brief

High complication burden in young adults with type 2 diabetes

A small study shows high complication rates in young people with type 2 diabetes.

03-16-2018 | Gestational diabetes | News

DUKPC 2018

Limiting weight gain after gestational diabetes diagnosis could help prevent complications

Women with gestational diabetes who gain weight late in pregnancy have an increased risk for adverse birth outcomes, study results presented at the 2018 Diabetes UK Professional Conference in London suggest.

Meet our Editorial Board

Lori BerardSanjay KalraJay ShubrookProfessor John Wilding

New Content Item Meet our Advisory Board

image credits